Bergen, Norway - Reference is made to the stock exchange announcement from BerGenBio ASA (the 'Company') dated 14 June 2023 regarding the final results of the rights issue of 2,500,000,000 new shares in the Company, raising gross proceeds of NOK 250 million, and the allocation and issuance to subscribers in the Rights Issue of one warrant for every two Offer Shares allocated to them and paid by them in the Rights Issue.

As announced on 14 June 2023, the Company issued 1,249,999,617 Warrants of which 1,181,842,935 remains outstanding. The outstanding Warrants are listed and tradable on the Oslo Stock Exchange until 8 April 2024 at 16:30 hours (CEST) under the ticker code 'BGBIS'. Warrants which are not exercised no later than 15 April at 16:30 CET will lapse with no compensation to the holders.

Each Warrant gives the holder a right to subscribe for one new share ('New Share') at an exercise price per share equal to the volume-weighted average price (VWAP) of the Company's shares on the Oslo Stock Exchange in the three last trading days prior to the first date on which the holder can exercise the Warrant in each exercise period less 30%, but in any event (i) not lower than the nominal value (NOK 0.10) and (ii) not exceeding the subscription price in the Rights Issue plus 30% (i.e. NOK 0.13).

Based on the criteria above, the exercise price per New Share in the last exercise period, 2 April 2024 to 15 April 2024, is NOK 0.1255.

Contact:

Martin Olin

Email: ir@bergenbio.no

Rune Skeie

Email: rune.skeie@bergenbio.com

Jan Lilleby

Email: jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO).

(C) 2024 Electronic News Publishing, source ENP Newswire